Granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis) is a rare systemic autoimmune disease belonging to the group of vasculitides, characterized by inflammation of small and medium-sized blood vessels. The disease may affect the upper and lower respiratory tract, lungs, kidneys, skin, nervous system, and other organs, requiring timely and comprehensive treatment.
When is treatment required?
Treatment is required in the presence of chronic inflammatory processes in the nasal cavity and paranasal sinuses, recurrent nosebleeds, cough, shortness of breath, chest pain, impaired kidney function, skin rashes, general weakness, and fever. Without adequate therapy, the disease may progress rapidly and lead to severe, life-threatening complications.
How is granulomatosis with polyangiitis treated?
Treatment of granulomatosis with polyangiitis is aimed at suppressing autoimmune inflammation and achieving sustained remission. Immunosuppressive therapy is used, including systemic glucocorticosteroids and cytotoxic agents. In selected cases, modern targeted and biologic therapies are applied. Treatment is carried out under strict monitoring of laboratory parameters, renal function, and respiratory system status. After remission is achieved, maintenance therapy is prescribed.
Treatment of granulomatosis with polyangiitis is provided in leading clinics in Belarus. Diagnostic evaluation includes immunological testing with determination of ANCA antibodies, as well as instrumental methods such as CT, MRI, and biopsy. Patients receive individualized treatment regimens based on disease activity and the extent of organ involvement. Comprehensive follow-up helps reduce the risk of complications and ensures long-term disease control.
